Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: Fibrosis but not race encourages relapse

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 9, 2011, Pages 747-753

  Shoeb, Dania ^a   Rowe, Ian A ^b   Freshwater, Dennis ^b   Mutimer, David ^b   Brown, Ashley ^c   Moreea, Sulleman ^d   Sood, Ruchit ^d   Marley, Richard ^a   Sabin, Caroline A ^d   Foster, Graham R ^e  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

ADOLESCENT; ADULT; AGE; AGED; ANTIVIRAL THERAPY; ARTICLE; ASIAN; CHILD; DIABETES MELLITUS; ETHNICITY; FEMALE; FIBROSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INDIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RELAPSE; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT RESPONSE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051789074     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283488aba     Document Type: Article

References (24)

1. Group WC. Global surveillance and control of hepatitis C. J Viral Hepat 1999;6:35-47.
2. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832. (Pubitemid 27129209)
3. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74(Pt 11):2391-2399. (Pubitemid 23332300)
4. Janjua NZ, Hamza HB, Islam M, Tirmizi SF, Siddiqui A, Jafri W, et al. Health care risk factors among women and personal behaviours among men explain the high prevalence of hepatitis C virus infection in Karachi, Pakistan. J Viral Hepat 2010;17:317-326.
5. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48:148-162. (Pubitemid 350191999)
6. D'Souza R, Foster GR. Diagnosis and treatment of hepatitis C. J R Soc Med 2004;97:223-225. (Pubitemid 38686048)
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965. (Pubitemid 32913521)
9. Hadziyannis SJ, Sette H Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
10. Mangia A. Short-duration therapy for hepatitis C: suitable for all? J Viral Hepat 2007;14:221-227. (Pubitemid 46452415)
11. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-134. (Pubitemid 47057730)
12. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47. (Pubitemid 47171919)
13. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African-American and Caucasian-American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-477. (Pubitemid 44142464)
14. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
15. Powis J, Peltekian KM, Lee SS, Sherman M, Bain VG, Cooper C, et al. Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat 2008;15:52-57. (Pubitemid 350243576)
16. Aghemo A, Rumi MG, Soffredini R, D'Ambrosio R, Ronchi G, Del Ninno E, et al. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther 2006;11:797-802. (Pubitemid 44497175)
17. FreshWater DA, O'Donnell K, Mutimer DJ. Inferior response of Asian versus non-Asian hepatitis C genotype 3 infection to combination antiviral therapy. J Viral Hepat 2008;15:115-119.
18. Nelson D, Benhamou Y, Chuang W-L, Lawitz E, Rodriguez-Torres M, Flisiak R, et al. Randomized trial of albinterferon alfa-2b for the treatment of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010;139:1267-1276.
19. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5:124-129. (Pubitemid 46096836)
20. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24:336-345.
21. D'Souza R, Glynn MJ, Ushiro-Lumb I, Feakins R, Domizio P, Mears L, et al. Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol 2005;3:910-917. (Pubitemid 41219295)
22. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-163.
23. Foster G, Hezode C, Bronowicki J-P, Carosi G, Weiland O, Verlinden L, et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve, genotype 2 and 3, hepatitis C patients: final results of study C209. 2010 Data presented at EASL, 2010 Vienna.
24. Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, et al. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat 2009;17:327-335.